U.S. court invalidates patent on Bristol hepatitis B drug
Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.
"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
- Obama makes rare campaign trail appearance, people leave early
- Two arrested in death of Saudi student in California: report
- Obama makes rare campaign trail appearance, some leave early
- Former 'American Idol' contestant Joanne Borgella dies at 32
- IBM to pay Globalfoundries $1.5 bln to take chip unit off its hands -WSJ